Glenmark Pharmaceuticals has launched Tevimbra (tislelizumab) in India, marking its entry into the immuno-oncology space. The drug received approval from the Central Drugs Standard Control Organization (CDSCO) and is intended for the treatment of certain advanced cancers, including non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC).
Tevimbra is a PD-1 monoclonal antibody originally developed by BeOne Medicines (formerly BeiGene). It is approved for use in combination with chemotherapy as a first-line treatment for locally advanced or metastatic NSCLC and as a second-line monotherapy for both NSCLC and ESCC. The drug works by targeting the PD-1 receptor to reactivate the immune system’s T-cells, enabling them to better identify and attack cancer cells.
According to Glenmark, this launch represents a key strategic move aimed at strengthening its oncology portfolio and improving access to next-generation cancer treatments in India. Alok Malik, President and Business Head for India Formulations at Glenmark, stated that with the growing burden of cancer in the country, the introduction of Tevimbra provides a much-needed, clinically proven, and affordable treatment option for Indian patients.
Tevimbra is already approved and available in several major global markets including the United States, European Union, China, and Australia. Its introduction in India is backed by strong clinical data from multiple Phase III trials. The market responded positively to the announcement, with Glenmark’s shares rising nearly three percent, reflecting investor optimism around the company’s expansion into advanced oncology therapeutics.